What does the evidence show about Pyrilutamide (KX-826)'s effects?

Read Off Label rates the evidence for Pyrilutamide (KX-826) as Weak and the benefit magnitude as med, producing an overall grade of C (4.9/10). Kintor Pharmaceutical.

What safety findings are reported for Pyrilutamide (KX-826)?

Pyrilutamide (KX-826) has a low-med risk profile in the database. Low-Med (topical; scalp irritation) Legal status: Investigational (China Phase 3; US Phase 2/3).

Rankings / Hormones & Endocrine

Pyrilutamide (KX-826)

Hormones & Endocrine · Topical androgen receptor antagonist

Tier C

Reviewed by Read Off Label · Last reviewed Jul 11, 2026 · How we grade

androgen-receptortopicalagainvestigational

4.9 / 10

Tier C

Ev 3 Bn 5 Sf 7

Bottom line

Read Off Label grades Pyrilutamide (KX-826) as C (4.9/10) based on weak evidence, med benefit magnitude, and a low-med-risk safety profile.

Kintor Pharmaceutical.

Studied, labeled, or reported-use context: Topical, applied to scalp twice daily — Investigational; not individualized guidance.

What the evidence says

Kintor Pharmaceutical. Topical AR antagonist for AGA: China Phase 3 ongoing; US Phase 2 results mixed (inconsistent primary endpoints), Phase 3 design under revision. Mechanistically similar to topical clascoterone. Industry-sponsored; not yet conclusive.

Mechanism

Topical androgen-receptor antagonist for androgenetic alopecia, blocking scalp DHT signaling locally to avoid the systemic sexual side effects of oral finasteride/dutasteride.

Studied, labeled, or reported dose & route

Topical, applied to scalp twice daily

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

clinicaltrials.gov

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Pyrilutamide (KX-826)'s effects?: Read Off Label rates the evidence for Pyrilutamide (KX-826) as Weak and the benefit magnitude as med, producing an overall grade of C (4.9/10). Kintor Pharmaceutical.
What safety findings are reported for Pyrilutamide (KX-826)?: Pyrilutamide (KX-826) has a low-med risk profile in the database. Low-Med (topical; scalp irritation) Legal status: Investigational (China Phase 3; US Phase 2/3).
What doses or routes are reported for Pyrilutamide (KX-826)?: Topical, applied to scalp twice daily This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Pyrilutamide (KX-826) work?: Topical androgen-receptor antagonist for androgenetic alopecia, blocking scalp DHT signaling locally to avoid the systemic sexual side effects of oral finasteride/dutasteride.

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.